EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, VivoSim Labs's Enterprise Value is €-0.48 Mil.
VivoSim Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-9.26 Mil. Therefore, VivoSim Labs's EV-to-FCF for today is 0.05.
The historical rank and industry rank for VivoSim Labs's EV-to-FCF or its related term are showing as below:
FRA:4OR'
s EV-to-FCF Range Over the Past 10 Years
Min: -11.3 Med: -0.93 Max: 1.25
Current: 0.04
During the past 13 years, the highest EV-to-FCF of VivoSim Labs was 1.25. The lowest was -11.30. And the median was -0.93.
FRA:4OR's EV-to-FCF is ranked better than 98.78% of 328
companies
in the Biotechnology industry
Industry Median: 14.86
vs FRA:4OR: 0.04
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
VivoSim Labs's PE Ratio (TTM) for today is calculated as:
VivoSim Labs's share price for today is €3.492.
VivoSim Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.829.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
VivoSim Labs EV-to-FCF Related Terms
VivoSim Labs EV-to-FCF Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VivoSim Labs's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's EV-to-FCF falls into.
VivoSim Labs's current Enterprise Value is €-0.48 Mil.
VivoSim Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a EV-to-FCF of 0.05 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #4 out of 328 companies in the Biotechnology industry, placing it in the top 1.2%.
Is VivoSim Labs' EV-to-FCF too high?
VivoSim Labs' current EV-to-FCF is 0.05. The Biotechnology industry median EV-to-FCF is 14.86. VivoSim Labs' value of 0.05 is 99.7% below this industry median. Based on the distribution chart, VivoSim Labs ranks #4 out of 328 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' EV-to-FCF compare to AZTR and GRI?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #4 out of 328 companies for EV-to-FCF. This places VivoSim Labs in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 14.86. VivoSim Labs' value of 0.05 is 99.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.86, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current EV-to-FCF of 0.05 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current EV-to-FCF is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current EV-to-FCF of 0.05. The stock's GF Value™ is €8.13, compared to a current price of €3.49 — trading 57% below its estimated fair value. The current EV-to-FCF is 0.05 and 99.7% below the Biotechnology industry median of 14.86. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current EV-to-FCF is 0.05 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 57% below its estimated GF Value™ of €8.13.
Key valuation signals for FRA:4OR:
EV-to-FCF: 0.05
GF Value™: €8.13 vs. price of €3.49 (57% below fair value)
Industry Position: 99.7% below the Biotechnology median (#4 of 328)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score
Get the complete analysis for FRA:4OR
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
